Home » Newsletters » BioWorld Science

BioWorld Science

May 12, 1997

View Archived Issues

Glaxo obtains license to technology and porphyrin compound for dermatological diseases

D-21266 demonstrates advantages over miltefosine in vivo

Positive preclinical results with CB-1267 in combination with 9-cis-RA for prostate cancer

In vivo efficacy and pharmacokinetic profile of XR-9051

TAS-103 shows antitumor activity against orthotopically implanted human cancers

Serine protease inhibitors described by 3-D

Modified p53 constructs prepared by the Wistar Institute

Antineoplastic/immunostimulating glycan discovered by U. of Illinois researchers

Prodrugs of calcitriol disclosed by Wisconsin Alumni Research Foundation

Selective beta3-agonists from Lilly

ET antagonists described by Ciba-Geigy Japan (Novartis)

ImmuLogic receives funds from NIH to develop cocaine vaccine

Schering-Plough evaluates novel farnesyltransferase inhibitor

RPR selects farnesyltransferase inhibitor for in vivo evaluation

Taiho discovers potent and selective cdc25PTP inhibitors

Parke-Davis develops new c-src TK inhibitors

Glycan-conjugated 5-FU for the treatment of hepatocellular cancer/metastases

Sequana and Boehringer Ingelheim expand alliance for asthma research

Retinoid-like compounds that induce apoptosis in cancer cells

Procter & Gamble and Hoechst Marion Roussel to comarket Actonel

Sonus and Valois collaborate on development of aerosol drug delivery system

Lilly prepares raloxifene analogs that reverse MRP-mediated resistance

Penederm receives approval for butenafine in Canada

Dual 5alpha-reductase type I/II inhibitor from Lilly for prostatic cancer

Alpha-Beta Technology acquires MycoTox and expands antifungal program

BioSpecifics receives grant to develop collagenase injection for Dupuytren's disease

Procept's topical microbicide shown to be contraceptive

Effects of L-692429 in obese and nonobese young men

Osaterone enhances bone formation in ovariectomized rats

Update on HemispheRx Biopharma's Ampligen

Hepatoprotective effects of ET antagonist TAK-044

Ono-4007 restores immune responses in tumor-bearing animals

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for July 2, 2025.
Unnatural Products joins Argenx in a $1.5B macrocyclic deal
BioWorld
Unnatural Products Inc. notched another collaboration by signing on with Argenx SE in a multitarget research collaboration. Unnatural Products, which is getting...
Exercise-mimicking compound offers alternative to GLP-1 therapies
BioWorld
An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
CMS eyes competitive bidding for CGMs, insulin pumps
BioWorld MedTech
The U.S. Centers for Medicare & Medicaid Services posted the draft home health rule for calendar year 2026, which includes a proposal to subject continuous...